年龄作为心房颤动患者中风的危险因素：新型口服抗凝剂时代在血栓预防中的意义。
Age as a Risk Factor for Stroke in Atrial Fibrillation Patients: Implications in Thromboprophylaxis in the Era of Novel Oral Anticoagulants.
作者信息
Mitrousi Konstantina, Lip Gregory Y H, Apostolakis Stavros
机构信息
University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom.
出版信息
J Atr Fibrillation. 2013 Jun 30;6(1):783. doi: 10.4022/jafib.783. eCollection 2013 Jun-Jul.
Abstract
Atrial fibrillation is associated with significant morbidity and mortality. There is a strong relationship between atrial fibrillation and aging, thromboembolism, stroke, congestive heart failure and hypertension. In addition, advanced age is a powerful risk factor for stroke and thromboembolism in patients with atrial fibrillation. For many years, vitamin K antagonists were the only approved anticoagulants for the management of atrial fibrillation. Lately new anticoagulants made their appearance and large trials have already shown their superiority against vitamin K antagonists. Since the arrhythmia is encountered frequently in the elderly, it is crucial to identify the beneficial effects of the novel oral anticoagulants in this particular patient population.
摘要
心房颤动与显著的发病率和死亡率相关。心房颤动与衰老、血栓栓塞、中风、充血性心力衰竭和高血压之间存在密切关系。此外，高龄是心房颤动患者发生中风和血栓栓塞的重要危险因素。多年来，维生素K拮抗剂是唯一被批准用于治疗心房颤动的抗凝剂。最近，新型抗凝剂问世，大型试验已表明它们优于维生素K拮抗剂。由于这种心律失常在老年人中经常出现，因此确定新型口服抗凝剂对这一特定患者群体的有益作用至关重要。
相似文献
1
Age as a Risk Factor for Stroke in Atrial Fibrillation Patients: Implications in Thromboprophylaxis in the Era of Novel Oral Anticoagulants.
J Atr Fibrillation. 2013 Jun 30;6(1):783. doi: 10.4022/jafib.783. eCollection 2013 Jun-Jul.
2
Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation.
Am J Med. 2016 Oct;129(10):1117-1123.e2. doi: 10.1016/j.amjmed.2016.05.007. Epub 2016 Jun 2.
3
Use of oral anticoagulants in complex clinical situations with atrial fibrillation.
Med Clin (Barc). 2018 Jun;150 Suppl 1:8-24. doi: 10.1016/S0025-7753(18)30666-3.
4
Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials.
Am J Med. 2015 Sep;128(9):1007-14.e2. doi: 10.1016/j.amjmed.2015.03.034. Epub 2015 Apr 22.
5
Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.
Can J Cardiol. 2011 Jan-Feb;27(1):74-90. doi: 10.1016/j.cjca.2010.11.007.
6
Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Clin Ther. 2017 Jul;39(7):1456-1478.e36. doi: 10.1016/j.clinthera.2017.05.358. Epub 2017 Jun 28.
7
[Non vitamin-K dependent oral anticoagulants (NOACs) in chronic kidney disease patients with non-valvular atrial fibrillation].
G Ital Nefrol. 2017 Apr;34(2):58-73.
8
Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.
Lancet. 2008 Jan 26;371(9609):315-21. doi: 10.1016/S0140-6736(08)60168-3.
9
'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey.
Am J Med. 2014 Jun;127(6):519-29.e1. doi: 10.1016/j.amjmed.2013.12.022. Epub 2014 Jan 28.
10
Benefits and risks of oral anticoagulation for stroke prevention in nonvalvular atrial fibrillation.
Thromb Res. 2012 Jan;129(1):9-16. doi: 10.1016/j.thromres.2011.09.023. Epub 2011 Oct 21.
引用本文的文献
1
Risk of left atrial appendage thrombus in older patients with atrial fibrillation.
Arch Med Sci. 2021 Mar 3;19(6):1721-1730. doi: 10.5114/aoms/126028. eCollection 2023.
2
Systematic review on traumatic intracranial haemorrhage in patients on anti-thrombotic medications; haemorrhage progression, thrombosis, and anti-thrombotic recommencement.
Neurosurg Rev. 2023 Jul 6;46(1):166. doi: 10.1007/s10143-023-02075-4.
3
Risk factors for left atrial thrombus in younger patients (aged < 65 years) with atrial fibrillation or atrial flutter: Data from the multicenter left atrial thrombus on transesophageal echocardiography (LATTEE) registry.
Front Cardiovasc Med. 2022 Oct 12;9:973043. doi: 10.3389/fcvm.2022.973043. eCollection 2022.
4
Risk Levels and Adverse Clinical Outcomes Among Patients With Nonvalvular Atrial Fibrillation Receiving Oral Anticoagulants.
JAMA Netw Open. 2022 Aug 1;5(8):e2229333. doi: 10.1001/jamanetworkopen.2022.29333.
5
Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care.
Eur Heart J Cardiovasc Pharmacother. 2022 Dec 15;9(1):47-57. doi: 10.1093/ehjcvp/pvac042.
6
Prevalence, clinical profile, and stroke risk of atrial fibrillation in rural Andhra Pradesh, India (The AP-AF study) - Rationale and design.
Indian Pacing Electrophysiol J. 2021 Sep-Oct;21(5):275-280. doi: 10.1016/j.ipej.2021.05.003. Epub 2021 May 16.
7
Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation.
Heart. 2022 Mar;108(5):345-352. doi: 10.1136/heartjnl-2020-318753. Epub 2021 May 11.
8
A Structured Literature Review and International Consensus Validation of FORTA Labels of Oral Anticoagulants for Long-Term Treatment of Atrial Fibrillation in Older Patients (OAC-FORTA 2019).
Drugs Aging. 2020 Jul;37(7):539-548. doi: 10.1007/s40266-020-00771-0.
9
Efficacy and Safety of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and High Thromboembolic Risk. A Systematic Review.
Front Pharmacol. 2019 Sep 19;10:1048. doi: 10.3389/fphar.2019.01048. eCollection 2019.
10
Switching to Another Oral Anticoagulant and Drug Discontinuation Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Different Direct Oral Anticoagulants.
Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619870249. doi: 10.1177/1076029619870249.
本文引用的文献
1
Atrial fibrillation and thromboprophylaxis in heart failure: the need for patient-centered approaches to address adherence.
Vasc Health Risk Manag. 2013;9:3-11. doi: 10.2147/VHRM.S39571. Epub 2013 Jan 16.
2
A review of oral anticoagulants in patients with atrial fibrillation.
Postgrad Med. 2012 Nov;124(6):7-16. doi: 10.3810/pgm.2012.11.2608.
3
Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey.
Thromb Haemost. 2013 Feb;109(2):328-36. doi: 10.1160/TH12-08-0539. Epub 2012 Nov 22.
4
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
Thromb Haemost. 2012 Nov;108(5):876-86. doi: 10.1160/TH12-03-0209. Epub 2012 Sep 26.
5
Risk of falls and major bleeds in patients on oral anticoagulation therapy.
Am J Med. 2012 Aug;125(8):773-8. doi: 10.1016/j.amjmed.2012.01.033.
6
Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents.
Europace. 2012 Mar;14(3):312-24. doi: 10.1093/europace/eur263.
7
Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice.
Thromb Haemost. 2012 May;107(5):838-47. doi: 10.1160/TH11-10-0718. Epub 2012 Feb 8.
8
Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
Thromb Haemost. 2012 Mar;107(3):584-9. doi: 10.1160/TH11-11-0784. Epub 2011 Dec 21.
9
Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA).
Thromb Haemost. 2011 Nov;106(5):868-76. doi: 10.1160/TH11-05-0358. Epub 2011 Sep 22.
10
Apixaban versus warfarin in patients with atrial fibrillation.
N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27.
Zotero 插件